Results 71 to 80 of about 19,745 (243)
Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies
OncoTargets and TherapyRecently, bispecific antibodies (BsAbs) are evolving the landscape of cancer treatment and have significantly improved the outcomes of relapsed or refractory cancer patients. As increasing BsAbs entered clinical practice, specific toxicities have emerged, and renal side-effects have been described.
Wen, Xiaoli, Xu, Gaosi
openaire +2 more sources
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, EarlyView.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Frontiers in ImmunologyBispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Zhijuan Ai +7 more
doaj +1 more source
American Journal of Hematology, EarlyView.ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter +13 more
wiley +1 more source
Effect of antibody levels on the spread of disease in multiple infections [PDF]
There are complex interactions between antibody levels and epidemic propagation, the antibody level of an individual influences the probability of infection, and the spread of the virus influences the antibody level of each individual. There exist some viruses that, in their natural state, cause antibody levels in an infected individual to gradually ...
arxiv +1 more source
Bispecific Antibodies Against HIV [PDF]
Cell, 2016 Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire +3 more sources
Application of humanized mice in the safety experiments of antibody drugs
Animal Models and Experimental Medicine, EarlyView.The graphical abstract of this review highlights the critical role of humanized mice in the safety evaluation of antibody drugs. First, the inherent immunogenicity of antibody drugs can lead to the production of antidrug antibodies and hypersensitivity reactions on repeated administration.
Zhimin Sun +9 more
wiley +1 more source
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
International Journal of Nanomedicine, 2018 Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H +5 more
doaj
A new approach to produce IgG4-like bispecific antibodies
Scientific Reports, 2021 While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao +5 more
doaj +1 more source
Angewandte Chemie International Edition, Accepted Article.CD59 is an immunomodulatory cell surface receptor associated with human disease. Despite its importance in complement regulation and bacterial pathogenesis, CD59 remains a challenging therapeutic target. Research to date has focused on antibody or protein‐based strategies.
Edward William Tate +12 more
wiley +1 more source